Rectal Cancer Recurrent Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Rectal Cancer Recurrent clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting

Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer

Colorectal, CancerColorectal Cancer RecurrentColorectal Cancer Stage III+1 more
City of Hope Medical Center200 enrolled1 locationNCT07226115
Recruiting

Stage II/III Colorectal Cancer Recurrence

Colorectal, CancerColorectal AdenocarcinomaColorectal Cancer Recurrent+2 more
City of Hope Medical Center400 enrolled4 locationsNCT06314958
Recruiting

Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy

Colorectal Cancer RecurrentColorectal PolypColorectal Adenoma
Peking Union Medical College Hospital150 enrolled1 locationNCT06957626
Recruiting
Early Phase 1

A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer

Colorectal Cancer MetastaticColorectal Cancer RecurrentColorectal Cancer Stage IV
Shanghai Changzheng Hospital20 enrolled1 locationNCT07050394
Recruiting
Phase 3

Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer

Colorectal Cancer MetastaticColorectal Cancer Recurrent
Second Affiliated Hospital, School of Medicine, Zhejiang University302 enrolled1 locationNCT06992648
Recruiting
Not Applicable

Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA

Colorectal Cancer Recurrent
Koo Foundation Sun Yat-Sen Cancer Center30 enrolled1 locationNCT06769828
Recruiting
Phase 2

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Lung CancerMelanomaPancreas Cancer+4 more
N.N. Petrov National Medical Research Center of Oncology20 enrolled1 locationNCT06229340
Recruiting
Phase 3

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

Rectal Cancer Recurrent
National Cancer Center Hospital East110 enrolled45 locationsNCT04288999